Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasalfent vs Morphine for Breakthrough Cancer Pain
NCT00589823Phase 3Completed
- Start
- Jun 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fentanyl (transdermal patch + oral transmucosal lozenge) in breakthrough cancer pain (BTcP) (2 arms). Primary endpoint: Pain Intensity Difference at 15 minutes. Started Jun 2007; status: completed.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00589823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00589823.